Logo

Eclipsebio eRibo Pro Service

Aug 15, 2023

Eclipsebio has launched its eRibo Pro service to identify differential transcription and translation as well as high-resolution mapping of ribosome positioning. Customers receive an interactive report with two data sets from a single sample: a ribosome-protected fragment library and an RNA-seq library. These data are intended to enable researchers to, for instance, quantify changes in transcription and translation in response to therapeutics, the San Diego-based company notes on its website. eRibo Pro incorporates exclusively licensed Ribo-seq technology developed by researchers at the University of California, San Francisco, the company noted.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.